Skip to Main Content

Paper Details

Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
J Clin Oncol
13
2023
AAP, Abiraterone, Enzalutamide, Men, Metastatic Castration-Resistant Prostate Cancer, abiraterone, abiraterone acetate, androgen, androgen receptor, enzalutamide, mCRPC, patients, prednisone, prostate-specific antigen
Author NameAffiliation
Michael J MorrisMemorial Sloan Kettering Cancer Center
Emmanuel S AntonarakisUniversity of Minnesota
Alan H BryceMayo Clinic
Himisha Beltran
Himisha Beltran
Mary-Ellen Taplin
Eric J SmallUCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco
  • 1 - 7

Datasets

Release 1.2